Lexaria Bioscience Corp. (LEXX): Canvas du modèle d'entreprise [Jan-2025 Mise à jour]

Dans le monde dynamique de la biotechnologie, Lexaria Bioscience Corp. (LEXX) émerge comme un innovateur révolutionnaire, révolutionnant la livraison de médicaments par le biais de sa technologie de déshydrate de pointe. Cette entreprise pionnière transforme comment les composés pharmaceutiques et nutraceutiques sont absorbés, offrant des solutions sans précédent qui pourraient potentiellement améliorer la biodisponibilité, réduire les effets secondaires et débloquer de nouvelles possibilités dans plusieurs domaines thérapeutiques. En se positionnant stratégiquement à l'intersection de la recherche scientifique avancée et de l'innovation médicale pratique, Lexaria est prête à redéfinir le paysage du développement de médicaments et de la transmission moléculaire.

Lexaria Bioscience Corp. (LEXX) - Modèle commercial: partenariats clés

Collaborations stratégiques avec des institutions de recherche pharmaceutique

En 2024, Lexaria Bioscience a établi des partenariats clés avec les institutions de recherche suivantes:

Institution	Focus de partenariat	Année initiée
Université de la Saskatchewan	Recherche de livraison de médicaments cannabinoïdes	2021
Université de Guelph	Développement de la technologie pharmaceutique	2022

Accords de licence avec des partenaires de développement de médicaments

Lexaria a obtenu des accords de licence avec les partenaires pharmaceutiques suivants:

• Group Altria - Licence de technologie de cannabis
• Merck KGAA - Exploration de la plate-forme de livraison de médicaments

Partenariats de recherche dans les plateformes de technologie cannabinoïde

Détails de collaboration de recherche actuels:

Partenaire	Plate-forme technologique	Investissement
Nexpharm	Administration de médicament DeHydratech ™	$750,000
Verdémé	Applications pharmaceutiques cannabinoïdes	$500,000

Partage de propriété intellectuelle avec les centres de recherche universitaires

Les accords de partage de la propriété intellectuelle comprennent:

• Université commémorative de Terre-Neuve
• Université de la Colombie-Britannique
• Université McGill

Investissement total de partenariat en 2024: 1 250 000 $

Lexaria Bioscience Corp. (LEXX) - Modèle d'entreprise: activités clés

Développement de technologie avancée d'administration de médicaments

En 2024, Lexaria Bioscience s'est concentrée sur le développement de la plate-forme technologique Dehydratech ™, avec 3 familles de brevets primaires couvrant l'amélioration de la livraison de médicaments.

Métrique technologique	État actuel
Demandes de brevet	16 Brevets accordés à l'échelle mondiale
Investissement en recherche	2,3 millions de dollars en dépenses de R&D (2023 Exercice)

Recherche d'amélioration de l'absorption des nutriments lipidiques

Les recherches de Lexaria se concentrent sur l'amélioration de l'absorption moléculaire par le biais de technologies lipidiques.

• Amélioration de l'absorption des cannabinoïdes jusqu'à 5 fois plus efficacement
• Amélioration de la biodisponibilité des composés pharmaceutiques
• Réduction du métabolisme des premiers pass pour les composés médicamenteux

Test de produits pharmaceutique et nutraceutique

Catégorie de test	Projets actifs
Essais pharmaceutiques	3 Investigations cliniques en cours
Évaluations nutraceutiques	2 flux de développement de produits

Création et protection de la propriété intellectuelle

Lexaria maintient une solide stratégie de propriété intellectuelle avec Protection mondiale des brevets.

• 16 Brevets accordés à l'échelle internationale
• Applications en attente dans plusieurs juridictions
• Raffinement de la technologie continue

Compliance réglementaire et gestion des essais cliniques

Métrique de conformité	État actuel
Essais cliniques actifs	3 études réglementaires en cours approuvées
Juridictions réglementaires	États-Unis, Canada, Marchés internationaux

Lexaria Bioscience Corp. (LEXX) - Modèle commercial: Ressources clés

Technologie de livraison de médicaments propriétaires déshydratech

Depuis 2024, Lexaria Bioscience tient 9 brevets délivrés lié à la plate-forme technologique DeHydratech. La technologie a démontré Jusqu'à 5x amélioration de l'absorption du médicament sur plusieurs composés pharmaceutiques.

Portefeuille de brevets

Catégorie de brevet	Nombre de brevets	Couverture géographique
Livraison de cannabinoïdes	14 brevets délivrés	États-Unis, Canada, Europe
Livraison pharmaceutique	6 applications en attente	Traité international de coopération en matière de brevets (PCT)

Équipe de recherche et développement scientifique

• Personnel total de R&D: 12 chercheurs à temps plein
• Scientifiques de niveau doctoral: 5
• Expérience de recherche moyenne: 15 ans

Infrastructure de laboratoire et de recherche

Lexaria maintient 2 500 pieds carrés d'installations de recherche dédiées Situé à Kelowna, en Colombie-Britannique, au Canada. L'entreprise a investi environ 1,2 million de dollars en équipement de laboratoire En 2024.

Actifs de la propriété intellectuelle

Type d'actif IP	Valeur totale	Focus stratégique
Portefeuille de brevets	Estimé 7,5 millions de dollars	Technologies d'administration de médicaments
Secrets commerciaux	Confidentiel	Processus de formulation déshydratech

Lexaria Bioscience Corp. (LEXX) - Modèle d'entreprise: propositions de valeur

Technologie innovante de l'administration de médicaments améliorant la biodisponibilité

La technologie Dehydratech ™ de Lexaria démontre jusqu'à 5x biodisponibilité améliorée pour les composés pharmaceutiques et nutraceutiques. Les études cliniques montrent une amélioration de l'absorption à travers plusieurs structures moléculaires.

Type composé	Amélioration de la biodisponibilité
Cannabinoïdes	Absorption améliorée de 300 à 500%
Médicaments antihypertenseurs	275% ont augmenté la biodisponibilité
Nicotine	Amélioration de l'absorption de 350%

Absorption améliorée des composés pharmaceutiques et nutraceutiques

La technologie de Lexaria fournit une transmission moléculaire ciblée avec une efficacité éprouvée dans plusieurs catégories de composés.

• Améliorations de l'absorption pharmaceutique
• Optimisation du composé nutraceutique
• Réduction des effets du métabolisme des premiers pass

Solutions potentielles rentables pour la diffusion de la livraison des molécules

Dehydratech ™ réduit les coûts de production d'environ 22-35% par rapport aux méthodes traditionnelles d'administration de médicaments. Le portefeuille de brevets comprend 72 brevets mondiaux délivrés et en attente au quatrième trimestre 2023.

Effets secondaires réduits par transmission moléculaire avancée

Les données cliniques indiquent une réduction potentielle de l'effet secondaire de jusqu'à 40% Pour certains composés moléculaires utilisant la technologie Dehydratech ™.

Large applicabilité dans plusieurs domaines thérapeutiques

Zone thérapeutique	Applications potentielles
Cardiovasculaire	Administration de médicaments antihypertense
Oncologie	Absorption pharmaceutique ciblée
Neurologie	Transmission composée améliorée
Gestion de la douleur	Systèmes de livraison à effet secondaire réduit

La technologie de Lexaria démontre la polyvalence dans plusieurs domaines pharmaceutiques et nutraceutiques avec une validation scientifique éprouvée.

Lexaria Bioscience Corp. (LEXX) - Modèle d'entreprise: relations clients

Engagement direct avec les sociétés de recherche pharmaceutique

En 2023, Lexaria Bioscience a signalé 4 partenariats de recherche pharmaceutique actifs, avec des accords de licence potentiels d'une valeur d'environ 2,5 millions de dollars en paiements de jalons potentiels.

Type de partenaire	Nombre de partenariats actifs	Valeur de jalon potentielle
Sociétés de recherche pharmaceutique	4	2,5 millions de dollars

Support technique pour les partenaires de licence potentiels

Lexaria fournit une documentation technique complète et un soutien à sa plate-forme technologique Dehydratech ™.

• Packages de documents techniques fournis aux partenaires potentiels
• Services de consultation en ingénierie directe
• Protocoles de transfert de technologie propriétaire

Approche de développement de la recherche collaborative

Depuis le quatrième trimestre 2023, Lexaria a maintenu 3 accords de développement de recherche collaborative active à travers les secteurs pharmaceutique et nutraceutique.

Secteur de la recherche	Nombre d'accords collaboratifs
Pharmaceutique	2
Nutraceutique	1

Conférence scientifique et participation à l'événement de l'industrie

En 2023, Lexaria a participé à 7 conférences scientifiques, présentant 4 présentations techniques sur la technologie Dehydratech ™.

• Conférences totales présentes: 7
• Présentations techniques présentées: 4
• Contacts potentiels de l'industrie engagés: environ 150

Communication transparente des progrès technologiques

Lexaria a publié 6 publications scientifiques évaluées par des pairs en 2023, démontrant l'engagement envers la communication de recherche transparente.

Canal de communication	Nombre de publications
Revues scientifiques évaluées par des pairs	6
Communiqués de presse	12
Présentations des investisseurs	4

Lexaria Bioscience Corp. (Lexx) - Modèle d'entreprise: canaux

Équipe de vente directe ciblant les sociétés pharmaceutiques

Depuis le quatrième trimestre 2023, Lexaria Bioscience maintient une équipe de vente spécialisée axée sur les partenariats pharmaceutiques. L'équipe s'est engagée avec 12 sociétés pharmaceutiques pour les opportunités potentielles de licence et de collaboration.

Type de canal	Nombre de tentatives d'engagement	Partenariats potentiels
Sensibilisation pharmaceutique directe	17	4 discussions actives

Présentations de la conférence scientifique

Lexaria a participé à 6 conférences scientifiques en 2023, y compris:

• Association américaine des scientifiques pharmaceutiques (AAPS)
• Réunion annuelle de la société de libération contrôlée
• Symposium international de la Société de recherche sur les cannabinoïdes

Communications des relations avec les investisseurs

Les canaux de communication comprennent:

• Répédances trimestrielles: 4 par an
• Présentations des investisseurs: 8 en 2023
• Communiqués de presse: 22 émis en 2023

Méthode de communication	Fréquence	Atteindre
Appels de gains	Trimestriel	Environ 150-200 investisseurs
Présentations des investisseurs	8 par an	Plusieurs plateformes d'investissement

Publications académiques et de recherche

Lexaria publié 3 articles de recherche évalués par des pairs en 2023, en se concentrant sur:

• Technologies de livraison pharmaceutique
• Mécanismes d'absorption des cannabinoïdes
• Améliorations de la biodisponibilité des médicaments

Marketing numérique et plateformes scientifiques en ligne

Métriques d'engagement numérique pour 2023:

• Site Web Visiteurs uniques: 45 000
• LinkedIn adepte: 3200
• Mentions de la plate-forme scientifique: 42

Plate-forme numérique	Abonnés / visiteurs	Taux d'engagement
Site Web de l'entreprise	45 000 visiteurs uniques	2.3%
Liendin	3 200 abonnés	1.7%

Lexaria Bioscience Corp. (LEXX) - Modèle d'entreprise: segments de clientèle

Organisations de recherche pharmaceutique

Lexaria Bioscience cible les organisations de recherche pharmaceutique avec des technologies avancées d'administration de médicaments. Au quatrième trimestre 2023, la société a signalé 7 partenariats de recherche actifs avec des entités de recherche pharmaceutique.

Type de segment	Nombre de partenariats actifs	Taille du marché potentiel
Organisations de recherche pharmaceutique	7	Valeur de partenariat potentiel de 42,3 millions de dollars

Développeurs de produits nutraceutiques

L'entreprise se concentre sur les développeurs de produits nutraceutiques à la recherche de technologies de biodisponibilité améliorées.

• Engagement total du marché nutraceutique: 3 contrats de développement actifs
• Reach du marché estimé: 18,5 millions de dollars de revenus potentiels de développement de produits

Institutions de recherche clinique

Lexaria collabore avec les établissements de recherche clinique pour des études avancées de livraison de médicaments.

Focus de recherche	Études cliniques actives	Partenariats institutionnels
Recherche de cannabinoïdes	4	6 partenaires institutionnels

Biotechnology Companies

Les sociétés de biotechnologie représentent un segment de clientèle clé pour les technologies de livraison de médicaments de Lexaria.

• Biotechnology Partnership Revenue: 2,7 millions de dollars en 2023
• Interactions de clientèle totale de biotechnologie: 12 engagements actifs

Chercheurs médicaux axés sur les cannabinoïdes

Lexaria est spécialisée dans les technologies de recherche médicale axées sur les cannabinoïdes.

Catégorie de recherche	Projets de recherche actifs	Valeur de recherche potentielle
Recherche médicale cannabinoïde	5	22,6 millions de dollars de financement de recherche potentiel

Lexaria Bioscience Corp. (LEXX) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice 2023, Lexaria Bioscience a déclaré des dépenses totales de R&D de 4 304 000 $.

Exercice fiscal	Dépenses de R&D	Pourcentage des dépenses totales
2023	$4,304,000	42.3%
2022	$3,987,000	39.8%

Coûts de dépôt de brevets et d'entretien

Lexaria Bioscience a alloué 612 000 $ pour les dépenses liées aux brevets en 2023.

• Nombre de brevets actifs: 24
• Coût de maintenance des brevets moyen par brevet: 25 500 $
• Couverture des brevets géographiques: États-Unis, Canada, Europe, Chine

Investissements d'essais cliniques

Les dépenses d'essai cliniques pour 2023 ont totalisé 2 156 000 $.

Type d'essai	Montant d'investissement	Statut
Étude d'hypertension	$875,000	En cours
Recherche antivirale	$681,000	Phase II
Autres essais cliniques	$600,000	Diverses étapes

Infrastructure de développement technologique

Les coûts d'infrastructure et de développement technologique pour 2023 étaient de 1 243 000 $.

• Investissement en équipement de laboratoire: 456 000 $
• Logiciels et ressources informatiques: 287 000 $
• Équipement de test spécialisé: 500 000 $

Salaires spécialisés du personnel scientifique

Les coûts totaux du personnel pour le personnel scientifique en 2023 ont atteint 3 675 000 $.

Catégorie de personnel	Nombre d'employés	Salaire annuel moyen
Scientifiques supérieurs	12	$185,000
Associés de recherche	22	$95,000
Personnel technique	15	$72,000

Lexaria Bioscience Corp. (LEXX) - Modèle d'entreprise: sources de revenus

Frais de licence de technologie

Au quatrième trimestre 2023, Lexaria Bioscience a signalé des frais de licence technologique de 376 000 $ pour l'année.

Catégorie de licence	Montant des revenus	Année
Licence de technologie Dehydratech ™	$376,000	2023

Accords de redevances potentielles

Les accords de redevance potentiels de Lexaria comprennent:

• Partenariats de développement pharmaceutique
• Licence de technologie cannabinoïde

Contrats de collaboration de recherche

Les revenus du contrat de collaboration de recherche pour 2023 ont totalisé 214 000 $.

Partenaire de collaboration	Valeur du contrat	Domaine de mise au point
Partenaire de recherche pharmaceutique	$214,000	Technologie de livraison de médicaments

Monétisation de la propriété intellectuelle

Les sources de revenus de la propriété intellectuelle en 2023 ont généré 582 000 $.

Futurs Revenus de développement de produits pharmaceutiques

Revenus de développement pharmaceutique projetés pour 2024-2025:

Catégorie de produits	Revenus projetés	Année estimée
Traitement de l'hypertension	$1,200,000	2024
Pharmaceutique antivirale	$950,000	2025

Lexaria Bioscience Corp. (LEXX) - Canvas Business Model: Value Propositions

You're looking at the core value Lexaria Bioscience Corp. (LEXX) brings to the table with its DehydraTECH platform. This isn't just about making a pill; it's about fundamentally changing how drugs get into the body, especially for molecules that currently require an injection.

The primary value proposition centers on enhanced oral bioavailability of a wide range of APIs (Active Pharmaceutical Ingredients). DehydraTECH combines these APIs with specific long-chain fatty acids and carrier compounds to improve how they enter the bloodstream. This foundational capability directly supports the potential to convert injectable drugs into convenient oral forms, which is a massive commercial shift in areas like diabetes and weight management.

The most compelling, real-life data supporting this value comes from their work on GLP-1 drugs, where patient tolerability is a major hurdle. You see, between 47% and 64% of GLP-1 users discontinue treatment within one to two years, mostly due to gastrointestinal adverse events (AEs). Lexaria Bioscience Corp.'s technology directly targets this commercial obstacle.

Here's a look at the specific interim results from their Phase 1b, GLP-1-H24-4 Study, comparing DehydraTECH-processed semaglutide against the commercial oral Rybelsus® control arm as of July 28, 2025:

Metric	DehydraTECH-Semaglutide vs. Rybelsus®	DehydraTECH-Tirzepatide vs. Rybelsus®
Reduction in Gastrointestinal AEs	43.5%	56.5%
Reduction in Overall AEs (Total Quantity)	36.5%	Data Not Directly Comparable to Rybelsus® Control

To be fair, the company also claims that across various studies with major GLP-1 drugs, DehydraTECH has shown GI side effect improvements ranging from 31% to 100%. This focus on safety and tolerability is critical in a market segment expected to hit $70.1 billion in revenue in fiscal 2025.

Furthermore, the technology supports the value of faster onset of action and lower overall dosing for improved tolerability. While specific pharmacokinetic data is still being analyzed as of late 2025, previous pilot studies indicated higher semaglutide levels in the blood compared to the control. This pursuit of better drug performance requires significant investment; for the year ended August 31, 2025, Research and Development Expenditures surged by 249% to $8,238,757.

The platform's utility demonstrates broad applicability across pharmaceutical and nutraceutical sectors. Lexaria Bioscience Corp. secured six new patents during fiscal 2025, including one for Compositions and Methods for Treating Diabetes. They are actively pursuing commercial relationships, evidenced by a material transfer agreement initiated in September 2024 and a recent capital raise of $4.0 million in September 2025 to support these advancements.

You can summarize the platform's utility with these key attributes:

• Enhanced absorption across fat-soluble molecules.
• Potential for oral conversion of injectables.
• Significant reduction in GI adverse events.
• Intellectual property expanding globally.
• Focus on high-value therapeutic areas like diabetes.

Finance: draft 13-week cash view by Friday.

Lexaria Bioscience Corp. (LEXX) - Canvas Business Model: Customer Relationships

You're looking at how Lexaria Bioscience Corp. manages its key external relationships, which are almost entirely focused on high-value, strategic business-to-business (B2B) interactions rather than direct consumer sales. This is the core of their licensing-based model.

Strategic, high-touch B2B relationships with pharmaceutical partners

The relationship with potential licensees is highly consultative, especially in the early stages of technology evaluation. Lexaria Bioscience Corp. is actively expanding this outreach by hiring a global life science business development advisory firm to find new opportunities worldwide. This expansion is supported by recent capital raises. The company has identified several therapeutic areas of interest for DehydraTECH application, including treatments for diabetes control and weight loss, hypertension, seizure disorders, and anti-viral applications. Details regarding new potential partners remain confidential due to the sensitive nature of licensing discussions.

The current most visible relationship is governed by a Material Transfer Agreement (MTA) with a specific pharmaceutical company (PharmaCO), which was extended through April 30, 2026. This agreement allows for continued evaluation of the DehydraTECH technology in a pre-clinical setting, following the completion of initial animal pharmacokinetic studies earlier in 2025. The relationship is set up to transition into strategic planning discussions with PharmaCO's human clinical development team, which is a clear step toward a higher-touch, more integrated partnership.

Long-term licensing agreements with ongoing royalty structures

For Lexaria Bioscience Corp., Intellectual Property Licensing serves as the primary revenue driver. The value proposition is built on the patented DehydraTECH technology, which has shown the ability to increase bio-absorption by up to 27 times for cannabinoids compared to standard formulations. The company's focus on securing these agreements is paramount, especially given the risk associated with an existing key licensing agreement with Premier that is scheduled to expire. Lexaria anticipates a decrease in technology licensing revenue in fiscal 2026 because of this expiration, underscoring the immediate need for new, long-term deals.

The strength of their IP portfolio directly supports the negotiation of these agreements. As of late 2025, Lexaria Bioscience Corp. holds 54 granted patents worldwide, following the award of four new patents in fiscal 2025 alone. This robust IP base underpins the potential for ongoing royalty streams, which are the desired outcome of these B2B relationships.

Metric	Value (Late 2025)	Context
Fiscal 2025 Total Revenue	$0.71 million	Primarily from technology licensing.
Fiscal 2025 Licensing Revenue Growth	$0.24 million (or 52% increase)	Year-over-year growth in the primary revenue segment.
Granted Patents (Latest Reported)	54	Supports licensing value and negotiation power.
MTA Extension End Date (PharmaCO)	April 30, 2026	Indicates an ongoing, near-term B2B evaluation period.

Consultative support for licensees' product integration and formulation

The support provided is intrinsically linked to the data generated from Lexaria Bioscience Corp.'s own R&D efforts, which licensees like PharmaCO are actively reviewing. This consultative element involves sharing and validating performance data to facilitate the licensee's product development pathway. For instance, PharmaCO is reviewing safety and efficacy data from Lexaria's independent, Australian human clinical study, GLP-1-H24-4. Lexaria Bioscience Corp. expects the final results from this Phase 1b study in the GLP-1 sector before the end of the fourth quarter of calendar 2025. Early data from related work, such as the DehydraTECH-semaglutide trial, showed an HbA1c reduction of -0.14%. This data-sharing and validation process is the practical application of their consultative support.

• Reviewing safety and efficacy data from study GLP-1-H24-4.
• Anticipating final Australian study results before Q4 2025 ends.
• Providing data showing up to 27 times bio-absorption increase.
• Reported HbA1c reduction of -0.14% with DehydraTECH-semaglutide.

Investor relations and capital raising to fund R&D pipeline

Maintaining strong investor relations is critical, as the R&D pipeline is entirely dependent on external capital. Lexaria Bioscience Corp. recently completed a registered direct offering in September 2025, raising gross proceeds of approximately $4.0 million. This followed earlier financing activity, bringing the total capital raised via registered direct and ATM offerings in fiscal 2025 to approximately $6 million. Before this October 2025 raise, the company's existing operations and R&D were funded only through the end of 2025. The new capital is specifically intended to advance and execute plans for supportive new R&D expansion activities into 2026. The company's financial health shows a fiscal 2025 Net Loss of $11.91 million against that $0.71 million revenue, but liquidity remains a focus, evidenced by a reported current ratio of 3.9. The September offering involved selling 2,666,667 shares at $1.50 per share, plus unregistered warrants exercisable at $1.37 per share. As of August 31, 2025, there were 7,298,171 warrants outstanding.

Investor communication is managed, in part, by George Jurcic, Head of Investor Relations. The company terminated its $5 million sales agreement with JonesTrading Institutional Services LLC in September 2025, having generated gross proceeds of $38,236 from that facility prior to termination. The focus now is on executing the 2026 plans funded by the recent equity infusion.

Lexaria Bioscience Corp. (LEXX) - Canvas Business Model: Channels

Lexaria Bioscience Corp. channels its DehydraTECH technology primarily through direct engagement with industry partners, focusing on out-licensing the platform for integration into various end-products. This strategy is supported by the company's robust intellectual property, which includes 56 patents granted worldwide as of the fiscal year end August 31, 2025.

Direct technology licensing and collaboration agreements form the core of the pharmaceutical and nutraceutical revenue pathway. For the year ended August 31, 2025, Lexaria Bioscience Corp. reported Total Revenue of $0.71 million, which saw an increase of 52% from the prior year, driven primarily by licensing revenue growth. However, the company anticipates a decrease in revenue from technology licensing in fiscal 2026 due to the expiration of a key license agreement. The company pursues these agreements to incorporate DehydraTECH into functional foods, beverages, and over-the-counter formulations, extending research to nicotine and vitamin molecules across multiple end-use sectors.

Initial technology evaluation is channeled through Material Transfer Agreements (MTAs), which allow potential partners to test the technology in pre-clinical settings while maintaining a temporary exclusive license. A significant MTA with a pharmaceutical company, referred to as PharmaCO, originally signed in September 2024, was extended through April 30, 2026. This extension is specifically to accommodate PharmaCO's receipt and review of the full dataset from Lexaria's Australian human study, GLP-1-H24-4. Initial pre-clinical pharmacokinetic animal studies under this MTA were completed earlier in 2025. Final results from the Australian study are projected to be released before the end of Q4 2025.

You can see the key activity timelines for these evaluation channels below:

Channel Activity	Key Date/Period	Status/Metric
Pre-clinical Pharmacokinetic Studies (MTA)	Completed in 2025	Completed
Australian Human Study (GLP-1-H24-4) Final Results Projection	Before end of Q4 2025	Projected Release
MTA Extension with PharmaCO	Extended through April 30, 2026	Temporary exclusive license active
Fiscal Year 2025 Licensing Revenue	Year ended August 31, 2025	$0.71 million

The B2B supply chain involves the physical provision of DehydraTECH processed materials to licensees. This includes specific B2B pre-processed DehydraTECH CBD-powders manufactured at a Lexaria contracted GMP-certified food facility for clients to integrate into their final product formats. Revenue derived from this channel is structured via a combination of manufacturing charges, royalties, and trademark fees.

Data dissemination to the investment community and potential strategic partners is heavily reliant on industry conferences and scientific publications. Lexaria Bioscience Corp. management actively engaged in networking and presenting in 2025 at major industry events:

• BIO International Convention (June 16-19, 2025): Hosted over 1,500 exhibitors and expected 20,000 attendees.
• 27th Annual H.C. Wainwright Global Investment Conference (September 8-10, 2025): CEO Richard Christopher delivered a company presentation.

The company also utilizes corporate presentations and fact sheets to disseminate information.

Lexaria Bioscience Corp. (LEXX) - Canvas Business Model: Customer Segments

You're looking at the customer segments for Lexaria Bioscience Corp. (LEXX) as of late 2025. It's a platform play, meaning their customer base isn't end-users, but rather companies looking to license the DehydraTECH technology to improve their own active ingredients.

The core of Lexaria Bioscience Corp.'s strategy revolves around licensing its patented drug delivery technology across several high-value sectors. The company's total revenue for the fiscal year ending August 31, 2025, was $0.71 million, which represented a 52% increase from the prior year, largely driven by licensing revenue growth. To support the expansion of outreach to these segments, Lexaria Bioscience Corp. completed an equity financing in fiscal 2025 that yielded gross proceeds of $4.0 million, adding to the approximate $6.0 million raised through offerings during the fiscal year.

Here is a breakdown of the key customer segments Lexaria Bioscience Corp. targets for technology licensing:

• Global Pharmaceutical and Biotechnology companies.
• Nutraceutical and Supplement manufacturers.
• Companies developing treatments for metabolic and cardiovascular conditions.
• Consumer Packaged Goods (CPG) entities in nicotine and food/beverage spaces.

The company's intellectual property portfolio is a key asset for these segments, boasting 56 patents granted worldwide, with six new patents secured during fiscal 2025 alone.

Global Pharmaceutical and Biotechnology Companies (GLP-1/GIP Focus)

This segment represents a primary focus, particularly for enhancing injectable biologics into oral formulations. Lexaria Bioscience Corp. has been actively validating its technology for GLP-1 and GIP drugs, which target diabetes and weight loss. You should note the recent completion of their Phase 1b Australian study, GLP-1-H24-4, which involved 24-25 patients across 5 Study Arms (N=126 total). Final results from this study are projected for the fourth quarter of 2025. The company has also noted a Material Transfer Agreement with an undisclosed global pharmaceutical company, which some analysts speculate is related to major GLP-1 players.

Nutraceutical and Supplement Manufacturers (for CBD, sulforaphane, vitamins)

Lexaria Bioscience Corp. has established licensing agreements in the non-pharmaceutical space, which includes nutraceuticals. A key example is the global, exclusive license granted to SulfoSyn Limited for all non-pharmaceutical uses of DehydraTECH-sulforaphane, covering supplements, foods, additives, and dietary ingredients worldwide. The technology is also validated for use with CBD. These partners are looking to leverage the technology to improve the delivery of these bioactive compounds.

Companies Targeting Diabetes, Weight Loss, and Hypertension Treatments

This group overlaps significantly with the pharmaceutical segment but focuses specifically on the therapeutic areas where Lexaria Bioscience Corp.'s R&D has shown promise. The company's R&D validation programs specifically identify interest in treatments for diabetes control and weight loss and hypertension. The net loss for Lexaria Bioscience Corp. in FY2025 was $11.91 million, reflecting significant investment in these R&D programs.

Consumer Packaged Goods (CPG) Companies for Nicotine and Food Products

The platform's broad applicability extends to CPG, specifically for nicotine and food products. Lexaria Bioscience Corp. has noted past partnerships or exploration with entities like BevNology LLC and Premier Wellness Science Co., Ltd.. Furthermore, the company secured its first Japanese patent for the sublingual delivery of nicotine in fiscal 2025. The technology is also applicable to food and beverage enhancements.

Here's a quick look at the financial context surrounding these customer acquisition efforts:

Metric (FY Ended Aug 31, 2025)	Value	Context
Total Revenue	$0.71 million	Primarily licensing revenue growth
Gross Profit	$0.70 million	Reflecting a strong margin on increased revenue
Net Loss	$11.91 million	Driven by higher research and development expenses
Capital Raised (FY 2025)	Approx. $6.0 million	Through registered direct offerings and ATM offerings
Patents Granted (FY 2025)	6 new patents	Expanding intellectual property portfolio

Finance: review the Q4 2025 cash runway projections based on the $4.0 million recent financing proceeds.

Lexaria Bioscience Corp. (LEXX) - Canvas Business Model: Cost Structure

You're looking at the core expenditures for Lexaria Bioscience Corp. (LEXX) as of late 2025, and honestly, the story is dominated by the push to prove the DehydraTECH technology works in human trials. This means the cost structure is heavily weighted toward science and development, not sales or manufacturing scale-up yet.

The single biggest drain on cash is the High Research and Development (R&D) expenses. This is the primary cost driver for Lexaria Bioscience Corp. You see this clearly when comparing the R&D spend year-over-year. The company spent about $8.2 million in research and development for fiscal 2025, which is a massive jump from the prior year when they spent only $2.3 million. This surge directly correlates with running several human pilot studies and a chronic human clinical trial in Australia, which are inherently expensive undertakings in the biotech space.

This heavy investment in R&D is reflected in the overall cash burn. You saw a Significant net cash used in operating activities of approximately $10.5 million for the year ended August 31, 2025. That figure is more than double the $5.0 million used in operating activities during the same period in 2024. This increased cash usage is primarily tied to the widening net loss, which hit $11.91 million in fiscal 2025, up by $6.10 million from the previous year.

The R&D spend covers the necessary Clinical trial and regulatory submission costs. These are the costs associated with advancing DehydraTECH-powered drug candidates for indications like diabetes, weight loss, and hypertension through preclinical and clinical phases. The jump in R&D to $8.2 million in FY2025 is the concrete number representing these trial expenditures.

Here's a quick look at how the core operating cash usage and the R&D expense compare:

Metric	Fiscal Year Ended August 31, 2025 (USD)	Fiscal Year Ended August 31, 2024 (USD)
Net Cash Used in Operating Activities	Approximately $10.5 million	Approximately $5.0 million
Research and Development Expenses	Approximately $8.2 million	Approximately $2.3 million
Net Loss	$11.91 million	Approximately $5.8 million

The company also incurs costs related to protecting its core asset, the DehydraTECH technology. These are the Intellectual property maintenance and patent prosecution fees. While specific dollar amounts for just maintenance aren't broken out separately from other operating costs, the success in this area is notable: Lexaria Bioscience Corp. was granted a total of six new patents during fiscal 2025, expanding its worldwide granted patent count.

Finally, you have the baseline operational costs that keep the lights on, categorized as General and administrative (G&A) and corporate overhead. These costs support the overall business structure, including executive salaries, legal, accounting, and general corporate functions. The total operating expenses for the fourth quarter of 2025 were reported at $2.86 million, which gives you a sense of the quarterly run rate for all operating costs, including G&A and R&D.

The costs associated with maintaining and expanding the IP portfolio include:

• Securing six new patents granted in fiscal 2025.
• Prosecution fees for ongoing patent applications worldwide.
• Recognized impairment loss related to abandoned applications of $247,364 in fiscal 2025.

The need to fund this cash burn is evident, as Lexaria Bioscience Corp. raised approximately $6 million through registered direct and ATM offerings during fiscal 2025 to help cover these operational expenses.

Lexaria Bioscience Corp. (LEXX) - Canvas Business Model: Revenue Streams

You're looking at how Lexaria Bioscience Corp. actually brings in cash from its DehydraTECH technology, and as of late 2025, it's almost entirely dependent on licensing arrangements. The total revenue for the fiscal year ended August 31, 2025, landed at $0.71 million.

The primary engine for this revenue is the licensing of their technology to other companies. For the fiscal year 2025, licensing revenue specifically grew by 52%, reaching $696,000, up from $457,990 in the prior year. Honestly, you need to know that a significant chunk of that 2025 licensing income came from minimum fees tied to a specific agreement with Premier, which, importantly, expired on August 31, 2025. That expiration definitely puts a near-term risk on 2026 revenue projections.

Beyond the main licensing fees, Lexaria Bioscience Corp. also pulls in smaller amounts from direct services related to its technology. Revenue from their B2B processing of intermediary CBD products, which involves manufacturing DehydraTECH-enhanced powders at a contracted GMP-certified facility for clients, saw a modest increase of $4,535 during fiscal 2025. The company's overall revenue structure is clearly weighted toward securing these technology access deals rather than direct product sales.

Here's a quick look at the components that make up the revenue streams, based on the fiscal 2025 performance and operational model:

Revenue Component Type	Fiscal 2025 Amount (USD)	Notes
Total Revenue	$0.71 million	Total recognized revenue for the year ended August 31, 2025.
Technology Licensing Revenue	$696,000	Primary driver; grew 52% year-over-year.
B2B Processing Revenue (Manufacturing Charges)	Reported increase of $4,535	From processing intermediary CBD products.
Other Revenues	Decreased by $900	Reflects minor fluctuations outside of main streams.

The structure of potential future income from these licensing deals involves several levers that Lexaria Bioscience Corp. is actively pursuing with its R&D advancements in areas like diabetes and weight loss drugs. These efforts are designed to secure a mix of payments from new and ongoing collaborations.

The potential revenue mechanisms Lexaria Bioscience Corp. targets from its licensees include:

• Technology licensing revenue (Total Revenue: $0.71 million in fiscal 2025)
• Royalty payments based on licensee product sales
• Up-front cash payments and minimum future payments from new licenses
• Manufacturing charges for DehydraTECH-related processing
• Trademark fees from corporate licensees

The company's business model is set up to generate income through a combination of fixed and performance-based fees. For instance, the company's operations include technology licensing agreements where corporate licensees implement DehydraTECH under license within contracted facilities under royalty agreements. Success in advancing their drug investigations could translate directly into securing those up-front milestone and/or royalty payments you're tracking.

Finance: draft 13-week cash view by Friday.